The civil money complaints, which carry a maximum penalty of $19,192 for a single violation, are intended to hold tobacco companies accountable for selling e-liquids—or vape juice—without FDA approval.
The FDA said Wednesday that for the first time, it has filed civil money penalty (CMP) complaints against 4 tobacco product manufacturers for manufacturing and selling e-liquids without marketing authorization.
The CMP complaints, which carry a maximum penalty of $19,192 for a single violation, are aimed at enforcing the federal Food, Drug, and Cosmetic (FD&C) Act’s premarket review requirements for new tobacco products. The FDA said it is seeking the statutory maximum allowed by law.
The FDA said it previously warned each of the companies that, by making and selling their products without marketing authorization, they were in violation of premarket requirements for tobacco products and that failure to correct the violations could lead to an enforcement action. It is illegal to manufacture, sell, or distribute e-liquids that the FDA has not authorized.
The companies continue to make and sell their unauthorized e-liquids despite the agency’s warnings, the FDA said.
“Holding manufacturers accountable for making or selling illegal tobacco products is a top priority for the FDA,” Brian King, PhD, MPH, director of the FDA’s Center for Tobacco Products, said in a statement. “We are prepared to use the full scope of our authorities to enforce the law—especially against those who have continued to violate the law after being warned by the agency.”
The 4 firms are:
The companies may pay the penalty, enter into a settlement agreement, request an extension of time to file an answer to the complaint, or file an answer and request a hearing.
Companies that do not take action within 30 days after receiving the complaint risk a default order imposing the full penalty amount.
Preventing Respiratory Illness and Death Through Tighter Air Quality Standards
June 1st 2021On this episode of Managed Care Cast, a research scholar at the Marron Institute of Urban Management at New York University discusses the latest findings in the Health of the Air report, which was presented at the recent American Thoracic Society 2021 International Conference.
Listen
Study Highlights Key RA-ILD Risk Factors, Urges Early Screening
November 20th 2024This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.
Read More
Preventing Respiratory Illness and Death Through Tighter Air Quality Standards
June 1st 2021On this episode of Managed Care Cast, a research scholar at the Marron Institute of Urban Management at New York University discusses the latest findings in the Health of the Air report, which was presented at the recent American Thoracic Society 2021 International Conference.
Listen
Study Highlights Key RA-ILD Risk Factors, Urges Early Screening
November 20th 2024This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.
Read More
2 Commerce Drive
Cranbury, NJ 08512